Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706
M. A. Hussein(Cleveland Clinic), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sheila M. Dobin(Baylor Scott & White Medical Center - Temple), Kenneth A. Foon(Markey Cancer Center), David R. Head(University of Southern California), David H. Boldt(The University of Texas at San Antonio Health Science Center), Laurence Elias(Pharmacyclics (United States)), G. Thomas Budd(Cleveland Clinic), Shaker Dakhil, Holly Gundacker(Seattle Cancer Care Alliance)
Cited by 8
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k